# Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

> **NCT03006302** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 41 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Epacadostat
- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** CRS-207
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** GVAX Pancreas Vaccine

## Key facts

- **NCT ID:** NCT03006302
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-31
- **Primary completion:** 2023-08-22
- **Final completion:** 2024-08-05
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-10-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006302, "Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03006302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*